ENTA - Enanta Pharmaceuticals, Inc.
119.59 -0.01 (-0.00%)
After hours: 5:35PM EDT
| Previous Close | 118.99 |
| Open | 119.43 |
| Bid | 108.00 x 1100 |
| Ask | 125.00 x 1400 |
| Day's Range | 118.15 - 121.75 |
| 52 Week Range | 33.15 - 122.43 |
| Volume | 244,322 |
| Avg. Volume | 198,026 |
| Market Cap | 2.304B |
| Beta | 1.45 |
| PE Ratio (TTM) | 45.81 |
| EPS (TTM) | 2.61 |
| Earnings Date | Aug 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 113.00 |
- InvestorPlace•7 days ago
2 Stable and 2 Speculative Biotech Stocks to Buy
Biotech stocks represent a peculiar conundrum. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. Thus, creating a list of biotech stocks to buy will always be a tough challenge.
- Business Wire•11 days ago
Enanta Pharmaceuticals Recognizes the 1st International NASH Day
Enanta Pharmaceuticals, Inc., (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, is proud to support the 1st International NASH Day taking place today. This is a ground-breaking event organized by the NASH Education Program and its benefactors and supporters around the world. NASH is expected to become the #1 cause of liver transplant by 2020 in the United States, and its prevalence is projected to increase globally in association with obesity and type 2-diabetes.
- ACCESSWIRE•16 days ago
Today's Research Reports on Stocks to Watch: Enanta Pharmaceuticals and Vascular Biogenics
NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Enanta Pharmaceuticals as well as Vascular Biogenics were two stocks in the biotech arena making big moves in Wednesday's trading session. Enanta climbed higher ...
- Zacks•22 days ago
Why Enanta Pharmaceuticals (ENTA) Could Shock the Market Soon
Although overlooked by the investors, Enanta Pharmaceuticals (ENTA) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.
- Business Wire•22 days ago
Enanta Pharmaceuticals to Present at the NASDAQ 38th Investor Conference Presentation to be Webcast on June 12 at 9:30 A.M. GMT
Enanta Pharmaceuticals, Inc., (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, President and Chief Executive Officer will make a presentation followed by a question and answer session at the NASDAQ 38th Investor Conference on June 12 at 9:30 a.m. GMT in London. A live webcast of the presentation will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com.
- Zacks•24 days ago
Bayer's Generic Competition, Pipeline Setback Issues Remain
Generic threats/competition for many of its products remain a concern for Bayer (BAYRY).
- GlobeNewswire•25 days ago
Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant S.A, 8point3 Energy Partners LP, Flexion Therapeutics, and Enanta Pharmaceuticals — New Research Emphasizes Economic Growth
NEW YORK, May 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Assembly ...
- Zacks•last month
Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y
Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.
- Market Realist•last month
Analysing NVR, DPZ, ENTA And QLYS Stocks
NVR’s (NVR) net income has grown at a 3-year and 5-year average of 24% and 24.3% respectively. The company’s pre-tax margin grew from 9.9% in 2013 to 13.4% in 2017. The stock prices have beaten the residential construction industry between 2013 and 2017. The stock was beaten in 2013 and 2016 by the S&P 500. The market cap had gained 188% between 2013 and 2017.
- Market Realist•last month
Total Returns and Sector Exposure for Growth Indexes—Continued
The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively. They have five-year annualized returns of 15% and 12.7%, respectively. They have YTD (year-to-date) returns of 5.4% and 6.1%, respectively.
- Zacks•last month
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.
- Zacks•last month
Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.
- Zacks•last month
Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion
Zoetis (ZTS) inks a definitive deal to acquire Caifornia-based Abaxis, for $83 per share in cash or a total of $2 billion.
- Zacks•last month
Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
- Zacks•last month
Roche's Actemra Gets FDA Nod for Subcutaneous Formulation
FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.
- Thomson Reuters StreetEvents•last month
Edited Transcript of ENTA earnings conference call or presentation 8-May-18 8:30pm GMT
Q2 2018 Enanta Pharmaceuticals Inc Earnings Call
- Zacks•last month
Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat
Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.
- Zacks•last month
Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss
Intrexon (XON) incurs narrower-than-expected loss but revenues missed mark in the first quarter of 2018.
- Zacks•last month
Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up
Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.
- Zacks•last month
Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses
Catalyst reported in-line loss in Q1. The company resubmitted a new drug application for its lead candidate Firdapse and expects FDA to accept the NDA in Q2.
- Zacks•last month
Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus
Ophthotech (OPHT) reports narrower year-over-year loss for the first quarter.
- Zacks•last month
VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters
VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.
- Associated Press•last month
Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot
The Watertown, Massachusetts-based company said it had profit of 61 cents per share. The biotechnology company posted revenue of $44 million in the period. Enanta Pharmaceuticals shares have increased ...
- Business Wire•last month
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2018
Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal second quarter ended March 31, 2018.
- Simply Wall St.•2 months ago
Calculating The Intrinsic Value Of Enanta Pharmaceuticals Inc (NASDAQ:ENTA)
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) as an investment opportunity. If youRead More...
